Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haemophilus influenzae type b polyribosylribitol phosphate polysaccharide–tetanus toxoid conjugate (PRP-T)
- Target
- PRP-T
- Molecular classification
- Other (bacterial capsular polysaccharide–protein conjugate, not a conventional biological target such as a receptor or enzyme)
01
Overview
Haemophilus influenzae type b polyribosylribitol phosphate polysaccharide–tetanus toxoid conjugate (PRP-T) is a vaccine antigen used in Hib conjugate vaccines to prevent invasive H. influenzae type b infections, primarily in infants and children. It consists of the capsular polysaccharide (PRP) of H. influenzae type b, covalently linked to tetanus toxoid protein, enabling a strong and lasting T cell–dependent immune response that results in generation of high-affinity anti-PRP antibodies and immunological memory. PRP-T is not itself a therapeutic target such as a receptor or enzyme; rather, it is the immunogenic component in Hib vaccines used for disease prevention[2][4][6].
- Other names
- Hib PRP–tetanus toxoid conjugateHib-PRP-TPRP-T conjugate
02
Mechanism of action
Induces anti-polyribosylribitol phosphate (PRP) antibody production via T cell–dependent immune response after conjugation to tetanus toxoid[2][4][6]
03
Biological functions
Immune response induction (as a vaccine antigen)
04
Disease associations
Infection (prevention of invasive Haemophilus influenzae type b disease)
05
Safety considerations
Injection site reactions (pain, redness, swelling)Mild fever or loss of appetiteExtremely rare risk of severe allergic reaction[2][6]
06
Biomarkers
Anti-PRP antibody titers (for efficacy monitoring)
Beyond the preview
Go deeper on Haemophilus influenzae type b polyribosylribitol phosphate polysaccharide–tetanus toxoid conjugate (PRP-T).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus influenzae type b polyribosylribitol phosphate polysaccharide–tetanus toxoid conjugate (PRP-T).